Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BFRA
CUSIPN/A
Phone011-49-2148-7600
Debt
Debt-to-Equity Ratio0.75
Current Ratio8.89
Quick Ratio8.08
Price-To-Earnings
Trailing P/E Ratio-14.67
Forward P/E Ratio-33.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.58 million
Price / Sales21.50
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)($0.90)
Net Income$-18,200,000.00
Net Margins-92.12%
Return on Equity-123.87%
Return on Assets-52.29%
Miscellaneous
Employees123
Outstanding Shares22,120,000
Market Cap$292.02 million
BIOFRONTERA AG/ADR (NASDAQ:BFRA) Frequently Asked Questions
What is BIOFRONTERA AG/ADR's stock symbol?
BIOFRONTERA AG/ADR trades on the NASDAQ under the ticker symbol "BFRA."
How were BIOFRONTERA AG/ADR's earnings last quarter?
BIOFRONTERA AG/ADR (NASDAQ:BFRA) announced its earnings results on Friday, August, 31st. The company reported ($0.23) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.14. The business earned $5.12 million during the quarter, compared to analyst estimates of $4.20 million. BIOFRONTERA AG/ADR had a negative net margin of 92.12% and a negative return on equity of 123.87%. View BIOFRONTERA AG/ADR's Earnings History.
When is BIOFRONTERA AG/ADR's next earnings date?
What price target have analysts set for BFRA?
2 brokers have issued 1 year price targets for BIOFRONTERA AG/ADR's stock. Their forecasts range from $19.00 to $20.00. On average, they anticipate BIOFRONTERA AG/ADR's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 47.7% from the stock's current price. View Analyst Price Targets for BIOFRONTERA AG/ADR.
What is the consensus analysts' recommendation for BIOFRONTERA AG/ADR?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOFRONTERA AG/ADR in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOFRONTERA AG/ADR.
Who are some of BIOFRONTERA AG/ADR's key competitors?
Some companies that are related to BIOFRONTERA AG/ADR include Vanda Pharmaceuticals (VNDA), Arrowhead Pharmaceuticals (ARWR), ImmunoGen (IMGN), Kiniksa Pharmaceuticals (KNSA), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Uniqure (QURE), CannTrust (CNTTF), Zai Lab (ZLAB), Rhythm Pharmaceuticals (RYTM), Lexicon Pharmaceuticals (LXRX), Revance Therapeutics (RVNC), Akorn (AKRX), Eagle Pharmaceuticals (EGRX) and Aptinyx (APTX).
Who are BIOFRONTERA AG/ADR's key executives?
BIOFRONTERA AG/ADR's management team includes the folowing people:
- Prof. Hermann Lübbert, Co-Founder, Chairman of Management Board & CEO (Age 62)
- Mr. Thomas Schaffer, CFO & Member of Management Board (Age 55)
- Mr. Christoph Dünwald, Chief Commercial Officer, Head of Sales & Marketing and Additional Member of Management Board (Age 50)
- Mr. Alexander Richardson, Head of UK Sales Team
When did BIOFRONTERA AG/ADR IPO?
(BFRA) raised $18 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 1,500,000 shares at $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.
How do I buy shares of BIOFRONTERA AG/ADR?
Shares of BFRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIOFRONTERA AG/ADR's stock price today?
One share of BFRA stock can currently be purchased for approximately $13.20.
How big of a company is BIOFRONTERA AG/ADR?
BIOFRONTERA AG/ADR has a market capitalization of $292.02 million and generates $13.58 million in revenue each year. The company earns $-18,200,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. BIOFRONTERA AG/ADR employs 123 workers across the globe.
What is BIOFRONTERA AG/ADR's official website?
How can I contact BIOFRONTERA AG/ADR?
BIOFRONTERA AG/ADR's mailing address is HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377. The company can be reached via phone at 011-49-2148-7600 or via email at [email protected]
MarketBeat Community Rating for BIOFRONTERA AG/ADR (NASDAQ BFRA)
MarketBeat's community ratings are surveys of what our community members think about BIOFRONTERA AG/ADR and other stocks. Vote "Outperform" if you believe BFRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BFRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
